BioCentury
ARTICLE | Clinical News

Seven-day contraceptive patch: Phase II data

September 8, 2008 7:00 AM UTC

Top-line data from an open-label, cross-over pharmacokinetic study in 39 patients showed that AG-200-15 produced EE and LNG levels that were less than with oral Levlen LNG/EE. No serious adverse event...